Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Galen Femring Includes HRT Class Labeling; Launch In June

Executive Summary

Labeling for Galen's vaginal hormone therapy Femring follows the template established for Wyeth's Premarin family to incorporate the findings from NIH's Women's Health Initiative study
Advertisement

Related Content

Warner Chilcott Femtrace Launch Expected In First Quarter 2005
Warner Chilcott Femtrace Launch Expected In First Quarter 2005
Galen in play
Galen in play
Galen Femring approved
Wyeth Low-Dose Prempro Approval Offers Message To Offset Safety Issues
Galen HRT Ring Femring Will Be Approved By February Or March, CEO Predicts
Hormone Therapy Class Labeling Uses Wyeth Template; Appeals Due By March
Lilly Sells Sarafem: Galen Adds Drug To Women’s Health Line For $295 Mil.
Prempro Cancer Risk Addressed In 550,000 Physician Letters, Label Review
Advertisement
UsernamePublicRestriction

Register

PS041527

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel